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Abstract
Background: The human respiratory syncytial virus (hRSV) is the leading cause of severe bronchiolitis in infants worldwide.
The most severe RSV diseases occur between 2 and 6 months-of-age, so pediatric vaccination will have to be started within
the first weeks after birth, when the immune system is prone to Th2 responses that may turn deleterious upon exposure to
the virus. So far, the high risk to prime for immunopathological responses in infants has hampered the development of
vaccine. In the present study we investigated the safety and efficacy of ring-nanostructures formed by the recombinant
nucleoprotein N of hRSV (N
SRS) as a mucosal vaccine candidate against RSV in BALB/c neonates, which are highly sensitive to
immunopathological Th2 imprinting.
Methodology and Principal Findings: A single intranasal administration of N
SRS with detoxified E.coli enterotoxin LT(R192G)
to 5–7 day old neonates provided a significant reduction of the viral load after an RSV challenge at five weeks of age.
However, neonatal vaccination also generated an enhanced lung infiltration by neutrophils and eosinophils following the
RSV challenge. Analysis of antibody subclasses and cytokines produced after an RSV challenge or a boost administration of
the vaccine suggested that neonatal vaccination induced a Th2 biased local immune memory. This Th2 bias and the
eosinophilic reaction could be prevented by adding CpG to the vaccine formulation, which, however did not prevent
pulmonary inflammation and neutrophil infiltration upon viral challenge.
Conclusions/Significance: In conclusion, protective vaccination against RSV can be achieved in neonates but requires an
appropriate combination of adjuvants to prevent harmful Th2 imprinting.
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Introduction
Human respiratory syncytial virus (hRSV) is a major cause of
severe lower respiratory tract infections in infants less than 6
months and in immuno-compromised or elderly patients [1,2,3,4].
Besides, infants who develop acute RSV bronchiolitis at an early
age are at increased risk for prolonged wheezing and future
development of asthma [5,6] through excessive priming of Th2
cells [7]. Bovine RSV (bRSV) is a closely related pneumovirus,
also causing severe and sometimes fatal respiratory disease in
calves [8].
Veterinary RSV vaccines exist but could be improved, whereas
several factors have impeded the development of an effective and
safe hRSV vaccine [9,10]. First of all, concerning a pediatric RSV
vaccine, safety will be of peculiar concern since, in the 60’s, a
vaccination trial with formaldehyde-inactivated virus in alum (FI-
RSV) led to an exacerbated disease upon seasonal RSV infection
in most vaccine recipients and two infants died with a prominent
pulmonary neutrophilia and moderate eosinophilia [11,12].
Extensive studies using rodent models have attributed disease
exacerbation to immunopathological responses: in adult BALB/c
mice, Th2 biased immune responses to the FI-RSV vaccine lead,
upon RSV challenge, to a pro-inflammatory ‘‘cytokine/chemokine
storm’’ promoting excessive pulmonary leukocyte infiltration, with
prominent eosinophilia, and goblet cell hyperplasia [13]. Second,
apart from the elderly, one major target population for vaccination
is the newborn or very young infant, with its relatively immature
innate and adaptive immune system prone to Th2-biased immune
responses [14], and potential interference of maternal antibodies
[15]. Third, adjuvants and/or delivery modes best adapted to elicit
protective and non pathogenic mucosal immunity in such very
young infants have yet to be improved and licensed. Interestingly,
studies in neonatal mice have suggested ways to reduce the Th2
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37722bias of neonatal responses to sub-unit protein vaccines, like the use
of CpG oligodeoxynucleotides as adjuvant [16,17].
Most of the RSV vaccines presently under development are
targeting the two surface glycoproteins F and G, which bear
epitopes recognized by neutralizing antibodies [10]. Much less has
been done to explore the potential interest as a vaccine component
of the nucleoprotein (N), although it was recognized as one of the
targets of T cell immunity, inducing both helper and cytotoxic T
cells in human [18,19]. Besides, N is highly conserved between
hRSV subtypes and even bears .85% amino-acid homology with
N from bRSV, so it could be an interesting component of a
heterosubtypic vaccine. Indeed, the combination of plasmids
encoding the RSV N and F proteins administered to calves or
infant rhesus monkeys was shown to provide protection without
causing disease exacerbation [20,21].
An original process was developed in our laboratory, allowing to
produce and purify large amounts of recombinant N from hRSV
as soluble ring structures composed of 10–11 N monomers bound
to random stretches of bacterial RNA (70 bp), which we named
N
SRS (for Sub-nucleocapsid Ring Structure) [22,23]. In a recent
paper, we documented its immunogenicity and vaccine potential,
when administered to adult BALB/c mice with, as adjuvant, the
mutant E. coli heat-labile toxin LT(R192G) (hereafter abbreviated
as LT) [24]. Nasal vaccination with N
SRS and LT elicited strong
local and systemic immunity characterized by high titers of anti-N
antibodies (IgA in the broncho-alveolar lavage (BAL) and serum
IgG1 and IgG2a), antigen specific CD8+ memory T cells and
IFNc producing CD4+ T cells in the absence of pathological lung
inflammation upon RSV challenge [24]. The same antigen
administered parenterally with a water-in-oil adjuvant (Seppic)
to colostrum-deprived one-month-old calves proved partially
protective against bRSV challenge, without inducing lung
eosinophilia or adverse lung inflammation [25].
In the present study, we chose to test our new mucosal vaccine
candidate in newborn (5 to 7 days old) BALB/c mice, a very
relevant animal model to address the risk of immuno-pathological
responses against RSV [26]. Indeed, a primary RSV infection in
BALB/c neonates leads to airway disease exacerbation with lung
eosinophilia upon re-infection at adult age [27]. Besides, FI-RSV
vaccination of BALB/c neonates has a more severe immunopath-
ological outcome upon virus challenge than the one elicited upon
FI-RSV vaccination of adult BALB/c mice [28]. We confirmed
the capacity of our vaccine to trigger efficient anti-viral immunity
after just one nasal administration to 5–7 days old pups. However
viral protection was associated with some disease exacerbation and
airway infiltration with neutrophils and eosinophils upon RSV
challenge, that appeared related to a Th2 neonatal imprinting.
Addition of a second pro-Th1 adjuvant (CpG oligodeoxynucleo-
tides) was able to restore a mixed Th1/Th2 immune memory and
abrogated eosinophilia with only a minor reduction of viral
protection upon challenge. Surprisingly, neonates treated with this
combination of adjuvants without antigen turned out to be equally
protected against virus replication.
Results
Neonatal nasal vaccination with N
SRS and LT(R192G)
provided viral protection but exacerbated lung disease
upon challenge
Five to seven days old pups received one intranasal (i.n.)
administration of N
SRS (3 mg) with or without adjuvant LT (2 mg)
(this vaccine formulation is noted thereafter N+LT). Mice
vaccinated as neonates where challenged 4 to 5 weeks later with
hRSV-A2. Mice were killed at day 5 post-challenge, which
allowed us to monitor the viral load, the weight loss and the onset
of the antibody response or lung inflammation in the same
individual mice. Pups for one experimental group were chosen
from at least two different litters and to reach a sufficient number
of pups in each experimental group allowing statistical analysis, we
combined data from several experiments (each experiment is
shown with a different symbol).
A single neonatal N+LT i.n. immunisation led to a strong
reduction of the viral mRNA load in the lungs 5 days after
challenge (Fig. 1A, N+LT versus unvaccinated RSV-infected
controls C+ p,0.001). Administered alone, LT did not reduce
the viral load and N gave partial and highly variable protection
(Fig. 1A, N versus C+ p,0.05).
As illustrated Fig. 1B, the RSV challenge induced a moderate
but significant weight loss from day 2 up to day 5 post-infection in
5 weeks-old mice (all infected groups versus uninfected littermates
[C2]p ,0.001). Weight loss was more severe in the N+LT
vaccinated group than in unvaccinated (C+) or N vaccinated mice
(N+LT versus C+ p,0.01; N+LT versus Np ,0.001). Neonatal
vaccination with LT alone also led to increased weight loss in most
mice (LT versus Np ,0.001, but LT versus C+ or N+LT p.0.05)
suggesting a contribution of LT to disease exacerbation.
Moreover, mice vaccinated as neonates with N+LT and
challenged with RSV as young adults had significantly more
leukocytes in their BAL at day 5 p.i. than unvaccinated infected
controls (C+) or mice vaccinated with N alone (Fig. 2A: N+LT
versus C+ p,0.001). Vaccination with LT alone also led to an
increased number of BAL leukocytes in most mice upon challenge,
although to a more variable and thus non significant level (LT
versus C+ p.0.05).
Determination of BAL cell subtypes by May-Gru ¨nwald-Giemsa
staining showed that the viral challenge per se did not alter
significantly BAL cell composition, except for a minor but
significant increase in the number of lymphocytes (Fig. 2B: C+
versus C2 p,0.0001). Vaccination with N or LT alone led to a
further and highly significant increase in BAL lymphocytes (LT
versus C+ p,0.001; N versus C+ p,0.01), neutrophils (Fig. 2C: LT
versus C+ p,0.01; N versus C+ p,0.001) and eosinophils (Fig. 2D:
LT versus C+ p,0.0001, N versus C+ p,0.001). Combining N+LT
in the neonatal vaccine further increased the number of
lymphocytes, neutrophils and eosinophils (N+LT versus C+:
p,0.0001 for the 3 subsets). Taken together, these data suggested
that both LT and N contributed to the inflammatory responses
recorded after the RSV challenge. As pulmonary eosinophilia was
suggestive of a Th2 biased memory response to N, we explored the
type of antiviral immunity primed by N+LT and investigated
further whether it could be modulated.
Neonatal vaccination with N+LT imprinted a Th2 biased
N-specific immunity, which could be modulated with
CpG
Sera collected before (d0) and 5 or 8 days after the viral
challenge (d5, d8 p.i.) were titrated by ELISA for anti-N
antibodies. As illustrated Fig. 3, anti-N antibody titers were at
baseline level in all groups before challenge (a month after
neonatal vaccination) but increased as early as 5 days and even
more so at 8 days after the RSV challenge in all N+LT vaccinated
mice, suggesting a memory response.
To further explore this hypothesis, we amplified the primary
neonatal response by a vaccine boost with N at 5 weeks. As shown
in Table 1 for N+LT primed mice, serum antibodies detected 7
days after the boost were mostly of the IgG1 subclass and no anti-
N IgA were detected in the BALF. To reduce the Th2 neonatal
imprinting, we decided to implement our neonatal vaccine
Neonatal RSV Vaccine
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neonates [16]. Indeed, contrarily to their N+LT primed
littermates, a few mice primed with N+CpG and most mice
primed with N+LT+CpG had high titers of IgG2a anti-N serum
antibodies, as well as detectable anti-N IgA in their BALF 7 days
after the N boost (Table 1).
Spleen and local lymph node (LN) cells, collected 7 days after a
boost with N, were cultured for 72 h in vitro with N, or with PMA-
Ionomycin and medium alone as positive and negative controls
respectively. Culture supernatants were assayed by ELISA for
IFNc, a Th1 cytokine and IL-5, a Th2 cytokine. As illustrated
Table 2, spleen and LN cells from N+LT primed pups boosted
with N produced both IFNc and IL-5, with the highest IL-5 titers
being produced by LN cells in some mice, confirming that
neonatal N+LT vaccination induced a Th2 biased local T cell
memory. By contrast, spleen and LN cells from mice primed with
N+LT+CpG or N+CpG produced higher titers of IFNc than of
IL-5, confirming that CpG added to the neonatal N+LT vaccine
reoriented memory T cells towards Th1 (Table 2).
Combining CpG and LT as adjuvants for neonatal
vaccination provided protection against viral challenge
without lung eosinophilia
In order to test whether CpG added to the neonatal N or N+LT
vaccine could also prevent disease exacerbation after challenge,
neonates vaccinated i.n. with N and/or LT and/or CpG were
challenged with RSV a month later.
Figure 1. Neonatal nasal vaccination with N+LT conferred viral protection but exacerbated airway disease upon RSV challenge.
Male and female pups (5–7 day-old) were vaccinated by intranasal instillation of 10 mL saline containing or not 3 mg N and 2 mg LT as indicated. At 5
weeks of age, mice were challenged by intranasal instillation of 50 mL (5.10
6 pfu) hRSV A2. Controls included unvaccinated infected (C+) and
uninfected (C2) littermates. Animals were killed 5 days post challenge (d5 p.i.). (A) Individual viral load assessed by qRT-PCR: R.Q. of N transcripts,
normalized to HPRT, are expressed as % of the unvaccinated infected control group (C+) (R.Q.=10062
2DDCt). Four independent experiments
combining different treatment groups are shown with $5 mice per group (C2:n=7 ,C +: n=10, LT: n=5, N: n=16, N+LT: n=20). Mann-Whitney U-
test was used for comparison between treatments (* p,0.05; *** p,0.001 and **** p,0.0001). (B) Mice were weighed daily from d0 till d5 p.i. and
individual weight loss/gain was calculated as % of initial weight. Data are mean6SEM from n$5 mice per group. Statistical analysis was performed to
compare growth over the period d2 to 5 p.i. using the Tukey’s multiple comparison test, repeated measures one way ANOVA (** p,0.01 and
*** p,0.001).
doi:10.1371/journal.pone.0037722.g001
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N+LT) was associated with a moderate increase in the number of
BAL leukocytes, that was not significant except between the
groups vaccinated with N+CpG versus N( p ,0.05, Fig. 4A).
Addition of CpG led to a slight increase in the number of
lymphocytes (except when added to LT alone, Fig. 4B), and,
whereas it did not reduce the number of neutrophils (Fig. 4C), it
nearly abolished BAL eosinophilia after challenge in each
formulation (Fig. 4D, N+CpG versus Np ,0.01, LT+CpG versus
LT and N+LT+CpG versus N+LT p,0.0001). FACS analysis of
BAL cell suspensions (Fig. 4E) confirmed that addition of CpG to
the N+LT neonatal vaccine abolished BAL eosinophilia (from
nearly 8% down to 0.3% SiglecF
+ CD11c
low CD45
+ BAL cells). As
expected, BAL leukocytes were mostly alveolar macrophages
(SiglecF
+, CD11c
+) for CpG vaccinated controls, whereas a
variable proportion of BAL leukocytes were double negative
Figure 2. LT and N contributed to the inflammatory responses recorded in BAL after the RSV challenge. Mice vaccinated as neonates as
in Fig.1 were killed 5 days post challenge (d5 p.i.). BAL cells were numerated, cytocentrifuged and stained with May-Gru ¨ndwald-Giemsa (MGG). Data
are mean6SEM from n$10 mice per group for total leukocytes (A), lymphocytes (B), neutrophils (C) and eosinophils (D) numbers. Mann-Whitney U-
test was used for comparison between treatments (** p,0.01; *** p,0.001 and **** p,0.0001).
doi:10.1371/journal.pone.0037722.g002
Figure 3. Neonatal N+LT nasal immunization primed for an early anti-N Ab response after the RSV challenge. Mice vaccinated as
neonates as in Fig.1 were bled before (day 0) and 5 or 8 days after the viral challenge with hRSV-A2 (d5 or d8 p.i.). Serum anti-N antibody titers were
assessed by an endpoint dilution ELISA assay on plates coated with N using HRPO-conjugated rabbit anti-mouse Ig(H+L) Abs. Individual titers and the
mean titer for day 0 (white circles, dotted line), d5 p.i. (grey circles, plain line) and d8 p.i. (black circles, plain line) are figured. Man-Whitney U-test was
used for comparison of titers at day 0, 5 and 8 p.i. for each group (** p,0.01; *** p,0.001).
doi:10.1371/journal.pone.0037722.g003
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37722(lymphocytes or neutrophils) for the N+CpG, N+LT or
N+LT+CpG vaccinated groups.
Histological examination of lungs collected 8 days post-
challenge (Fig. 5) showed few diffuse peribronchiolar infiltrates
in the lungs from C+ (data not shown) or LT+CpG vaccinated
mice (Fig. 5A, 5D). On the opposite, lung sections from mice
vaccinated with N+LT (Fig. 5B, 5E) or N+LT+CpG (Fig. 5C, 5F)
displayed large peribronchiolar and perivascular immune infil-
trates mostly composed of mononuclear cells, which clearly
suggested the development of bronchus associated lymphoid tissue
(iBALT). Although the average iBALT area/lung section (n$2
mice/group) was not statistically different (Fig. 5G), eosinophils
(indicated with red asterix) were frequently observed at the
periphery of these infiltrates in lung sections from N+LT (Fig. 5E)
but were rarely found in lung sections from N+LT+CpG
vaccinated pups (Fig. 5F).
We then investigated whether vaccine formulation could modify
the pattern of expression of several chemokines that could affect
the Th1/Th2 balance and the recruitment of eosinophils. The
levels of expression of mRNAs encoding the murine chemokines
mCCL2 (MCP1), mCCL11 (Eotaxin-1), mCCL3 (MIP1a and
mCCL5 (RANTES) were assessed by quantitative real time PCR
in lungs collected 5 days after the viral challenge (Fig. 6). As
opposed to mice administered CpG alone in the neonatal period,
which tended to have reduced levels of all four chemokine
transcripts after challenge, N+LT+CpG vaccinated mice had
significantly increased levels of CCL2 and CCL3 mRNA (Fig. 6A
and 6C), whereas N+LT vaccinated mice had significantly
increased levels of CCL11 (Fig. 6B) compared to the other groups
(N+LT versus C+ p,0.05; N+LT versus N+LT+CpG p,0.01). This
observation is consistent with the recruitment of BAL eosinophils
following challenge in N+LT vaccinated mice as opposed to their
absence when CpG were added to the vaccine formulation. The
level of expression of CCL5 was not significantly affected by
vaccination (Fig. 6D).
We next tested whether addition of CpG to the vaccine
formulation influenced weight loss, antibody production or viral
load after an RSV challenge. Adding CpG to the neonatal N+LT
vaccine abrogated the increase in weight loss after the RSV
challenge (N+LT versus N+LT+CpG p,0.05) (Fig. 7A). N+LT
primed mice produced mostly IgG1 anti-N antibodies as early as 5
days after the viral challenge (Fig. 7B). Addition of CpG to N or
N+LT primed for an early rise in IgG2a anti-N antibodies,
resulting in a more balanced IgG2a/IgG1 response in some mice,
although the differences between groups were not statistically
significant, due to highly variable individual titers.
Finally, as illustrated on figure 7C, neonatal administration of
CpG alone significantly decreased the viral load in the lungs on
day 5 p.i. (CpG versus C+ p,0.05) and combining CpG with LT
even led to an almost complete ‘‘non-specific’’ protection against
challenge (LT+CpG versus C+ p,0.01). Under these conditions,
adding N to CpG or LT+CpG did not significantly improve
protection although the level of protection elicited by N+LT
vaccination remained slightly better (N+LT versus N+LT+CpG
p,0.05) (Fig. 7C).
Thus efficient protection against RSV during the neonatal
period could be achieved by combining the non-specific stimula-
tory effects of LT and CpG and antigenic priming with N.
Discussion
In the present study we investigated in BALB/c neonate mice
the safety and efficacy of a new mucosal vaccine candidate against
RSV, which we previously validated in adult BALB/c mice [24].
BALB/c neonatal mice (#7 days of age) have been considered as
best approximating immune maturity of #2 months old babies
[29] an age when RSV vaccination should be undertaken, since
the most severe RSV disease affects mostly 2 to 6 month-old
infants. Several studies addressing the issues of optimizing
conditions for neonatal vaccination and, in peculiar, reducing
the Th2 bias of neonatal immune responses have been performed
using BALB/c neonates [16,30]. Moreover BALB/c neonates
constitutes a most sensitive experimental model for assessing
immunopathological imprinting as generated by FI-RSV vacci-
nation [28] or by an early RSV infection [26]: the propensity of
the host to develop a skewed Th2 response to RSV at an early age
set the stage for subsequent development of an asthma-like
phenotype on re-exposure to the same virus [27,31,32].
Our present data show that neonatal mucosal vaccination with
N+LT can generate efficient viral protection, resulting in over
95% reduction of the viral load, 5 days after a viral challenge with
RSV at early adult age. Yet, this neonatal vaccination induced a
prolonged state of hyper-reactivity to the virus, as shown by an
increased weight-loss and an infiltration of the broncho-alveolar
compartment by neutrophils and eosinophils a few days after the
Table 1. Anti-N antibody responses primed by neonatal nasal
vaccination shifted from IgG1 to IgG2a and IgA isotypes when
CpG were added as adjuvant.
Serum BALF
Prime
(a) IgG1 IgG2a IgA
N+LT 16946836
(b) 4/4
(c) 53619 1/4 #30 / 5
N+CpG 4936395 3/6 375163397 1/6 5621 / 6
N+LT+CpG 7646396 9/9 152361252 5/9 10616 / 9
LT+CpG 46612 2/8 #30 0/8 #30 / 2
(a)Neonates were immunised i.n. at age 5–7 days as indicated (prime) and
received one intranasal boost with N (10 mg) at 5 weeks. Sera and BALF were
collected 7 days after the boost.
(b)Antibody titers against N were determined by ELISA using endpoint dilution
assay. Data are mean6SEM (#30 or #3: not detected at the first tested dilution
for sera or BALF).
(c)Number of responders/number tested.
doi:10.1371/journal.pone.0037722.t001
Table 2. Memory T cell responses primed by neonatal nasal
vaccination shifted from Th2 to Th1 cytokine profile when
CpG were added as adjuvant.
Spleen
(b) LN
(b)
Prime
(a) IFNc
(c) IL-5 IFNc IL-5
N+LT 6546159
(d) 966 14316650 5116361
N+CpG 614620 ,7606 6 7 697 112678
N+LT+CpG 22686734 7625 8 0 6112 64646
LT+CpG 357698 7631 8 2 6123 865
(a)Neonates were immunised i.n. at age 5–7 days as indicated (prime) and
received one intranasal boost with N (10 mg) at 5 weeks.
(b)Spleen and cervical lymph node (LN) were collected 7 days after the boost (LN
were pooled from 2 to 3 mice). Single cell suspensions were cultured with N,
PMA-ionomycin or medium for 72 hours.
(c)Culture supernatants were assayed by ELISA for IFNc and IL5.
(d)Cytokine concentrations in supernatants from cultures restimulated with N
(mean pg/mL 6SEM for n$2 for spleen and pool of 2 for LN). (All cell cultures
responded to PMA, producing 3983868542 pg/mL IFNc).
doi:10.1371/journal.pone.0037722.t002
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observed in our first evaluation of the N+LT vaccine in adult
BALB/c mice [24], which underscores the usefulness of the
neonatal BALB/c mouse model for assessing the safety of a new
RSV vaccine candidate, as previously stated by Plotnicky et al
[28].
Individual weight-losses post-challenge were moderate (rarely
over-passing 5–10% for 2–3 days), as compared to 15–20%
weight-loss after challenge if mice had been primary infected as 4–
6 days-old pups ([27] and our own unpublished data) or
vaccinated as adults with M2 peptide with another mutant of
LT (LT-K63) as adjuvant [33]. Yet, average weight-loss was
significantly higher (over the period d2 to d5 p.i.) in the N+LT
vaccinated group as compared to N-vaccinated or unvaccinated
mice. As this suggested some vaccine (or adjuvant) exacerbated
disease, we monitored lung inflammation by differential enumer-
ation of the BAL leukocytes: clearly both the LT(R192G) adjuvant
and, concerning eosinophils, the N
SRS antigenic component of the
neonatal vaccine contributed to the recruitment of granulocytes in
the broncho-alveolar space after the viral challenge, which did not
occur in unvaccinated age-matched infected controls. Again, the
magnitude of this inflammatory reaction was far below that seen in
neonatally infected mice reinfected at adult age (e.g. eosinophilia
reaching over 35% of BAL cells, [27,31] and our own unpublished
data). Comparing a large set of data from individual mice
belonging to our different vaccination groups, we found a highly
Figure 4. CpG added to the neonatal vaccine abrogated BAL eosinophilia upon RSV challenge. Mice vaccinated as neonates as in Fig.1,
with or without addition of 2 nmoles CpG (ODN 1826), as indicated, were sacrificed 5 days after the viral challenge with hRSV-A2. BAL leukocytes
were numerated, cytocentrifuged and stained with May-Gru ¨nwald-Giemsa (MGG). Data are mean6SEM from n$10 mice per group combining three
independant experiments. Mann-Whitney test was performed to compare the total number of leukocytes (A), as well as the number of lymphocytes
(B), neutrophils (C) and eosinophils (D) (** p,0.01; *** p,0.001 and **** p,0.0001). (E) BAL cells from each experimental group were pooled (n$5
mice per group) and stained for FACS analysis using Siglec-F-PE, CD45-PerCP and CD11c-Biotin monoclonal antibodies followed by Streptavidine
APC. Isotype control stainings (ICS) were done with irrelevant isotype-matched antibodies on a pool of BAL cells from all experimental groups. After
gating on CD45
+ leukocytes (R1) and excluding autofluorescent cells (R2), eosinophils were detected as Siglec-F
+ and CD11c
low. Data analysis was
performed using FlowJo software with at least 5.000 events in the (R1 not R2) gate. Dot plots represent one of two experiments with similar data.
doi:10.1371/journal.pone.0037722.g004
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PMN cells in BAL (p,0.0001 for neutrophils, p,0.01 for
eosinophils). This suggested that vaccination has set the stage for
inflammatory responses that could contribute to protection upon
viral challenge. Interestingly eosinophils have been proposed to
promote RSV clearance [34] and were exonerated from
contributing to vaccine-enhanced disease in experiments under-
taken in adult mice [35,36].
Anti-N antibodies were rarely detected in the serum of N or
N+LT vaccinated mice one month after neonatal vaccination, but
an early anti-N antibody response could clearly be induced in most
N+LT vaccinated mice by an RSV challenge or by a boost with N.
Figure 5. Neonatal nasal vaccination with N+LT or N+LT+CpG augmented cellular infiltration in lung tissue upon RSV challenge.
Mice vaccinated as neonates as indicated or non vaccinated littermates were sacrificed 8 days after the hRSV-A2 challenge. Lung were dissected out,
fixed, embedded in paraffin and sectioned at 5 mm. Lung sections were then stained with hematoxylin-eosin-saffron and photographed using a
Nanozoomer (Hamamatsu). One representative section per group is shown (A–C: original magnification 2.56) with red asterix figuring eosinophils in
the enlarged selected area (D–F: enlargement 206). (G) Total iBALT area was measured using the NDPview software (Hamamatsu) for one
representative lung section of each mouse (n$2 mice per group). Data are mean6SEM.
doi:10.1371/journal.pone.0037722.g005
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SRS was
immunogenic in neonates and this N-specific antibody response
could be boosted by an RSV infection. The almost exclusive
production of IgG1 antibodies suggested that the immune memory
resulting from neonatal N+LT vaccination was Th2 biased. Yet,
we did not detect anti-N IgE antibodies upon neonatal vaccina-
tion, nor after the vaccine boost or viral challenge (data not
shown), as was the case after a primary neonatal RSV infection
followed by a challenge at adult age ([37] and our own
unpublished data).
That neonatal i.n. vaccination with N+LT also primed for N-
specific memory T cells was confirmed by the fact that spleen and
respiratory lymph node cells isolated a week after a vaccine boost
secreted both IFNc and IL-5 upon in vitro restimulation with N.
Once again the relatively high amount of the Th2 cytokine IL-5
secreted by local lymph node cells, suggested that the neonatal
priming with N+LT had opened the way to a Th2 biased local
memory.
Our experimental settings are very similar to those reported by
VanCott et al. who vaccinated i.n. 7 d old BALB/c pups with the
recombinant VP6 protein of EDIM rotavirus together with the
same LT(R192G) adjuvant and induced a substantial level of
protection against an oral EDIM virus challenge administered one
month after vaccination [38]. Neither serum IgG/IgA nor stool
IgA anti-VP6 antibodies could be detected in most mice before
challenge, as was the case for anti-N antibodies in our
experiments. However, splenocytes collected one month after the
neonatal vaccination, before any vaccine boost or viral challenge,
were shown to contain and/or secrete mostly IFNc, and almost no
IL-5, leading the authors to suggest that protection involved
immune Th1 cells.
In many other studies, however, vaccination of BALB/c
neonates with peptide or protein antigens led to Th2 biased
immune responses [39]. Furthermore, primo-infection with hRSV
in BALB/c neonates has also been shown to induce Th2 biased
immune responses: mediastinal lymph node cells from mice primo-
infected as pups respond with high IL-5 and reduced IFNc
secretion upon restimulation in culture with RSV infected,
irradiated syngeneic splenocytes, in opposition to the responses
of spleen or LN cells from mice primo-infected as adult [40].
Several mechanisms have been proposed at the molecular level
to explain the Th2 bias of BALB/c neonates. First, the Th2
cytokine locus is hypomethylated during the neonatal period, thus
allowing rapid high-level Th2 gene transcription (IL-4, IL-5 and
IL-13) [41]. Second, neonatal memory Th1 cells express high level
of interleukin 13 receptor a1 (IL-13Ra1) which heterodimerizes
with IL-4Ra, making Th1 cells prone to apoptosis driven by IL-4
produced by activated Th2 cells [42]. Finally, we have recently
demonstrated that lung neonatal T cells have Th2 features and
that the number of conventional and plasmacytoid dendritic cells
is severely reduced in neonatal lungs [43].
Nevertheless it is possible to achieve Th1 immune responses in
the neonatal context. For instance, several studies showed that
addition of CpG to a neonatal vaccine can help to reduce the Th2
bias of the immune response [16,17,44]. Indeed adding CpG to
our N+LT neonatal vaccine not only reduced the Th2 bias of the
recall response to a boost with N (less IL-5, more IgG2a), but also
abrogated eosinophilia following an RSV challenge, as assessed in
BAL cells. These observations are highly consistent with the
significant decrease in mCCL11 (eotaxin) mRNA that we have
recorded in the lungs when CpG were added to the N+LT
vaccine.
However addition of CpG to the N+LT vaccine did neither
reduce the neutrophilia in BAL post-challenge, nor the inflam-
matory leukocytic infiltrates in lung sections. Correlations have
been reported between the pattern of chemokine production and
the severity of RSV disease in infants [45,46] or with the Th1/Th2
immunopathological imprinting induced by RSV infection after
prior sensitization to individual RSV proteins (F or G) in adult
BALB/c mice [47]. According to these studies, the enhanced level
of expression of CCL2 and CCL3 mRNA upon challenge of our
N+LT and N+LT+CpG vaccinated mice, is consistent with mixed
Figure 6. CpG added to the neonatal vaccine decreased pulmonary CCL11 mRNA expression upon RSV challenge. The level of
expression of genes encoding mCCL2 (A), mCCL3 (C), mCCL5 (D) and mCCL11 (B) was monitored by quantitative real time PCR of RNAs extracted
from individual lungs collected at d5 p.i. Data were normalized to the mHPRT and expressed relative to the unvaccinated infected control group (C+)
(R.Q.=10062
2DDCt). Data are mean6SEM from n$4 mice per group (Mann Whitney test, * p,0.05). Two independent experiments were done.
doi:10.1371/journal.pone.0037722.g006
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mRNA) inflammatory settings, and could explain the increased
number of BAL neutrophils. Interestingly, CCL3 was recently
shown to protect against TNFa-mediated weight-loss and illness
after a primary RSV infection in adult mice [48].
Both N+LT and N+LT+CpG neonatal vaccination conferred
highly significant reduction of the viral load. However, the level of
Figure 7. CpG added to the neonatal vaccine reduced weight loss, increased secondary IgG2a response and maintained viral
protection upon RSV challenge. Mice vaccinated as neonates as indicated or non vaccinated littermates (C+) were sacrificed 5 days after the
hRSV-A2 challenge. Data from 2 independent experiments combining different treatment groups are shown with $5 mice per group (C+: n=7, CpG:
n=5, N+CpG: n=6, LT+CpG: n=5, N+LT: n=10, N+LT+CpG: n=11). (A) Mice were weighed daily from d0 till d5 p.i. and individual weight loss/gain
was calculated as % of initial weight. Statistical analysis was performed to compare growth over the period d2 to d5 p.i. using the Tukey’s multiple
comparison test, repeated measures one way ANOVA (* p,0.05; ** p,0.01 and *** p,0.001). (B) IgG1 and IgG2a anti-N antibodies were titrated by
ELISA in sera collected 5 days after the challenge. Data are mean6SEM from n$5 mice per group. (C) Individual viral load in lungs: R.Q. of N
transcripts, normalized to HPRT, are expressed as % of the mean of unvaccinated infected control group (C+) (R.Q.=10062
2DDCt). Data from 2
independent experiments combining different treatment groups are shown. Mann-Whitney U-test was used for comparison between treatments
(* p,0.05; ** p,0.01; *** p,0.001 and **** p,0.0001).
doi:10.1371/journal.pone.0037722.g007
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to some innate effect on the neonatal immune system since CpG
and even more so LT+CpG alone very significantly reduced lung
viral load, extending a previously described observation by Cho
and al. [49]. Nevertheless, N+CpG vaccinated mice were not
protected against RSV replication as efficiently as were the N+LT
or N+LT+CpG vaccinated mice, suggesting that a combination of
the stimulation of innate immunity by CpG, favoring Th1
responses, and the stimulation of N-specific immunity by the LT
adjuvant, both contributed to protection.
N
SRS are nanostructures which could by itself confer them
innate immunostimulatory properties: indeed, protein nanocages
of quite similar structure and size delivered intranasally to adult
mice were shown to induce iBALT development and to confer
protection against several respiratory viruses [50]. Accordingly, in
our own experiments, histological examination of lungs collected
early after the RSV challenge showed clear development of
iBALT along the main bronchi, if mice had been vaccinated as
pups with N+LT or with N+LT+CpG. Interestingly, neonatal
mice were recently shown to be particularly prone to iBALT
induction upon inflammatory (LPS or CpG) stimuli, with IL-17
being essential to iBALT development in the neonatal period [51].
Thus, although intranasal vaccination may seem a logical route
for protection against respiratory pathogens because it will
efficiently prime local immune effectors, it can also potentiate
inflammatory responses through local priming of Th17 memory
cells [52]. We did not look for these immune mediators in the
present study but we are keen to evaluate other delivery route like
the intradermal or transcutaneous routes, able to generate
systemic and local immunity with increased safety and feasibility
in the neonatal context [53]. Significantly, a double LT mutant
(dmLT) with even lower toxicity than LT(R192G) has been
developed [54]. Finally, we currently explore whether our N
SRS
nanoparticles could be used as carrier to improve immunogenicity
of peptides encoding major RSV neutralizing epitopes from F and
G envelope proteins.
Thus we believe that a safe and efficient pediatric vaccine
against RSV will require innovative solutions through adapted
combination of antigen, adjuvant and delivery route. Our present
work confirms that safety and efficacy of RSV vaccine candidates
should be evaluated in the most sensitive neonatal models.
Materials and Methods
Ethics statement
All animal experiments were carried out under the authority of
licence issued by the Direction des Services Ve ´te ´rinaires (accred-
itation number 78–115 to A. P-C.) and approved by the ethics
committee COMETHEA (COMite ´ d’ETHique applique ´a `
l’Expe ´rimentation Animale INRA Jouy-en-Josas et AgroParis-
Tech): authorization number 11/036. All efforts were made to
minimize suffering.
Vaccine formulation and virus
The production and purification of the recombinant N protein
from hRSV (Long strain) in E. coli, as sub-nucleocapsid ring
structures of 10–11 monomers of N bound to random stretches (70
bases) of bacterial RNA (N
SRS refered as N) have been described
previously [23,24]. For use as a vaccine, an additional filtration on
EndoTrap redH columns (Hyglos GMBH, Germany) reduced
endotoxin contamination to ,1 EU/mg protein (QCL-1000 LAL
assay, Cambrex).
The detoxified mutant E. coli enterotoxin LT(R192G), provided
endotoxin free by Prof. Clements (Tulane University, New
Orleans, USA) was kept sterile at 4uC. Phosphorothioate- CpG
oligodeoxynucleotides (ODN) 1826 (TCCATGACGTTCCT-
GACGTT) was purchased from Sigma Genosys, resuspended in
injectable water as a 1 mM stock solution and kept frozen at
220uC.
The hRSV strain A2 (provided by Prof. Openshaw, Imperial
College, Saint Mary’s Hospital, London) was propagated and
titrated by plaque assay on HEp-2 monolayers using avicel-
containing overlay media to control virus spread. Five days after
infection, lived cells were stained with crystal violet and plaque
forming units (pfu) were numerated.
Animals and immunization-challenge protocols
Male and female BALB/c mice purchased from the Centre
d’Elevage Janvier (Le Genest, St Isle, France) were bred and
housed under FELASA pathogen-free conditions in our animal
facilities (IERP, INRA, Jouy-en-Josas).
Five to seven days old pups of both sexes were vaccinated by
intranasal instillation of 8 to 10 mL of 0.9% endotoxin-free NaCl,
containing or not 3 mgN
SRS and/or 2 mg LT(R192G) and/or
2 nmoles (12.7 mg) CpG ODN 1826 (Sigma-Aldrich). Each
treatment was administered to 4 to 8 pups from at least 2 different
litters, in order to minimize individual variations.
Since a limited number of pups could be included, handled and
infected at the same time in any given experiment, all desired
control groups could not be included in each experiment. Hence,
experimental data presented in the figures usually comprise data
from two or more independent experiments.
At 5 to 6 weeks of age, mice were anesthetized by an
intraperitoneal injection of Avertine (2.5 mg/g of body-weight of
2-2-2-tribromoethanol, Aldrich) and received, by intranasal
instillation either a vaccine boost (10 mgN
SRS in 25 mL of saline),
or a challenge RSV infection (50 mL, 5.10
6 p.f.u. of hRSV-A2).
Individual daily weight was recorded until mice were killed 5 or 8
days after challenge, which allowed us to monitor the viral load,
the weight loss and the onset of the antibody response and lung
inflammation in the same individual mice.
Sample collection
Sera were obtained from blood collected via retro-orbital
puncture before (d0) and 7 days after a boost immunization, or 5
to 8 days after a challenge infection.
Mice were killed by cervical dislocation and the spleen and local
lymph nodes (LN) (cervical and maxillary LN draining the upper
respiratory tract and mediastinal LN) were dissected out in
complete RPMI medium (RPMI 1640, Gibco BRL, supplemented
with 10% heat-inactivated FCS, 2 mM L-Glutamine, Penicillin
and Streptomycine).
The left bronchus was clamped and the left lobe of the lungs was
snap-frozen in liquid nitrogen, and kept frozen at 280uC until
processed for RNA extraction for qRT-PCR assays.
Broncho-alveolar lavages (BAL) were performed by flushing the
other lobes of the lungs via tracheal puncture four times in and out
with 0.7 mL Ca
2+ and Mg
2+-free PBS supplemented with 1 mM
EDTA. BAL fluids were centrifuged and supernatants (BALF)
were stored frozen at 220uC for ELISA assays of anti-N
antibodies or cytokines. BAL cells were resuspended in complete
RPMI medium and adjusted to appropriate concentrations for
cytocentrifugation or FACS analysis.
Alternatively, the lungs were gently filled with 0.5 mL of 10%
paraformaldehyde (PFA) via the trachea and preserved in 10%
PFA at 4uC until processed for histological examination.
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chemokine expression by quantitative Real-Time PCR
Frozen lungs (left lobes) were resuspended in 0.6 mL lysis buffer
(Qiagen RTL buffer plus 0.1% 2-mercaptoethanol, Merck) in V
bottomed microtubes containing 0.1 mL of 1 to 1.2 mm ceramic
beads (Mineralex, Bron, France) (both RNAse free) and vortexed
for 15 s at 6000 rpm using a bead grinder homogenizer (Precellys
24, Bertin Technologies, Ozyme, St Quentin en Yvelines, France).
Total RNA were extracted from lung homogenate using RNA
minikit columns (Qiagen), with a 15 min DNase treatment (RNase
free DNase set, Qiagen), according to the manufacturer’s
instructions. Eluted RNA were quantified at 260 nm using a
Nanodrop (Labtech, France). Individual RNA samples (4 mg) were
reverse transcribed for 1 h at 42uC, using 300 U of M-MLV
Reverse Transcriptase (SuperScript II, Invitrogene) with 7 mMo f
random hexanucleotide primers (pd(N)6, Pharmacia Biotech),
15 nmol of each dNTP, 5 mM DTT and 60 U of ribonuclease
inhibitor (RNaseOUT, Invitrogen) according to the manufactur-
er’s instructions.
The primers (from Sigma–Aldrich, aliquoted and stored frozen
as 100 mM solutions at 220uC) used to target either a conserved
region of the N gene (position 42 to 125 of huRSV A2, [24]), or the
murine HPRT gene, or the CCL2, CCL3, CCL5 and CCL11 murine
chemokine genes (design with http://mouseprimerdepot.nci.nih.
gov/) are listed in Table 3.
Real time PCR was run in 96 well microplates on a Perkin
Elmer ABI Prism 7900HT Sequence Detector. For determination
of the viral load or of CCLx gene expression, individual cDNA
(1 mL diluted in 10 mL RNAse-free water) were mixed with 15 mL
SYBR GREEN PCR Master Mix (Applied Biosystems) containing
300 nM of both N primers, 500 nM of both CCLx primers or
500 nM of both HPRT primers, in triplicate for each gene. Non-
template controls were run in each assay. Fluorescence curves
were analyzed using the software Sequence Detector System (SDS
2.3, Perkin-Elmer) to determine the cycle threshold (Ct) values for
each gene. Individual data were normalized to HPRT, by
calculating the DCt value {Ct(N or CCLx)median -
Ct(mHPRT)median} and the DDCt {sample DCt - mean DCt of
at least 3 unvaccinated infected controls (C+)} were calculated for
each sample. Viral load was expressed as % of unvaccinated
infected controls (using the formula R.Q.=10062
2DDCt). The
viral load data from our qRT-PCR assay showed strong
correlation with those from our tissue culture plaque assay (Fig.
S1, r=0.99, p,0.001).
Similarly, the expression of the chemokine transcripts normal-
ized to mHPRT transcripts are expressed relative to unvaccinated
infected controls (C+) (R.Q.=2
2DDCt).
May-Gru ¨nwald-Giemsa staining and histology
BAL cells from individual mice, were numerated, spread on
duplicate microscope slides (Superfrost, Thermo, France) by
cytocentrifugation (5 min, 700 rpm, Cytospin 5, Shandon, France)
and stained with May-Gru ¨nwald and Giemsa. At least 400
leukocytes were counted blindly for each sample.
Lungs collected d8 p.i. were fixed in 10% paraformaldehyde,
embedded in paraffin and 5 mm sections, stained by hematoxylin,
eosin and saffron were photographed using a Nanozoomer
(Hamamatsu).
N-specific antibody E.L.I.S.A.
Individual mouse sera and BALF were assayed for N-specific
antibodies (Ig(H+L), IgG2a, IgG1 or IgA) by ELISA as previously
described in [24]. End-point antibody titers were calculated by
regression analysis, plotting dilution versus A450 using Origin
software (regression curve y=(b+cx)/(1+ax). Endpoint titers were
defined as the highest dilution resulting in an absorbance value
twice that of non-immune control sera or BALF.
IFN-c and IL-5 production by immune spleen or lymph
node cells
Red-blood cell depleted leukocyte suspensions were prepared as
previously described [24] from individual spleens or lymph nodes
(LN: cervical and mediastinal pooled from 2 to 3 mice) collected 7
days after a boost with N. Spleen or LN cells resuspended in
RPMI complete medium and 50 mM 2-Mercaptoethanol were
seeded in 96 wells microplates (4.10
5 cells/well) and co-cultured in
triplicates with N (10 mg/mL) or PMA-Ionomycin (10 ng/mL and
1 mg/mL, respectively) or culture medium. After 72 h at 37uC
with 5% CO2, supernatants for each condition were pooled and
stored frozen at 220uC.
Supernatants were assayed for IFNc and IL-5 by standardized
ELISA assays as previously described [24]. Briefly, for IFNc we
used mAb R4-6A2 for capture and biotinylated XMG1.2 for
revelation (BD biosciences) and murine rIFNc (R&D systems)
diluted from 3300 to 1.5 pg/mL in duplicate wells to establish a
standard curve. For IL-5, we used mAb TRFK5 for capture and
biotinylated TRFK4 (BD biosciences) for revelation and murine
rIL5 (R&D systems) diluted from 1000 to 7.5 pg/mL in duplicate
wells to establish a standard curve. Cytokine concentrations were
determined using the Revelation software (Dynex).
Flow cytometry
After a first 20 min blocking step using anti-CD32/CD16
(FcBlock, BD bioscience, 5 mg/ml or 10 mg/ml for highly
inflammatory BAL collected post-infection), BAL cells were
labeled with anti-CD45-PerCP, anti-Siglec-F-PE and anti-
Table 3. List of primers used for quantitative real time PCR.
Name of gene Forward primer (59 to 39) Reverse primer (59 to 39)
N (huRSV-A2) AGATCAACTTCTGTCATCCAGCAA TTCTGCACATCATAATTAGGAGTATCAAT
mHPRT CAGGCCAGACTTTGTTGGAT TTGCGCTCATCTTAGGCTTT
mCCL2 GGGATCATCTTGCTGGTGAA AGGTCCCTGTCATGCTTCTG
mCCL3 GATGAATTGGCGTGGAATCT CTGCCCTTGCTGTTCTTCTC
mCCL5 CCCACTTCTTCTCTGGGTTG GTGCCCACGTCAAGGAGTAT
mCCL11 TAAAGCAGCAGGAAGTTGGG CATCTGTCTCCCTCCACCAT
doi:10.1371/journal.pone.0037722.t003
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Pharmingen).
Cells were then fixed in 10% Cellfix (BD bioscience) and data,
acquired on at least 5,000 CD45+ leukocytes with a FACSCalibur
(BD Biosciences), were analyzed with Flow Jo software. After
gating on CD45
+ leukocytes and excluding autofluorescent cells,
BAL eosinophils were gated as Siglec-F
+, CD11c
lo/2 according to
[55].
Statistical data analysis
Data were expressed as arithmetic mean 6 standard error of the
mean (SEM). Non-parametric Mann-Whitney (two groups),
ANOVA Tukeys multiple comparison test (.2 groups) or
Spearman correlation statistical tests were used to compare
unpaired values (GraphPadPrism software). Values of p,0.05
were considered significant, levels of significance are indicated on
the graphs with stars : * p,0.05; ** p,0.01; *** p,0.001; and
**** p,0.0001.
Supporting Information
Figure S1 Correlation between viral load titration by
plaque assay and q-RT-PCR. Five infected and two non-
infected adult mice were sacrificed 4 days after the hRSV-A2
challenge. The lungs were cut in two equal parts and the viral load
was titrated either by plaque assay on HEp-2 monolayers, or by
qRT-PCR: R.Q. of N transcripts, normalized to HPRT, are
expressed as % of the infected mice (C+) (R.Q.=10062
2DDCt).
Non parametric Spearman correlation test was used to calculate a
correlation coefficient (r), (*** p,0.001).
(TIF)
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